The charisma of subgroups and the subgroups of CHARISMA

New England Journal of Medicine

Volumn 354, Issue 16, 2006, Pages 1744-1746

  Pfeffer, Marc A ^a   Jarcho, John A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTERY DISEASE; BLEEDING; BLOOD TRANSFUSION; BLOOD VESSEL INJURY; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; EDITORIAL; GENERAL PRACTITIONER; GENOTYPE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NULL HYPOTHESIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZATION; RISK REDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 33645881922     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068061     Document Type: Editorial

References (14)

1. Patrono C, Rodríguez LAG, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. [Erratum, BMJ 2002;324:141.]
3. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71.
5. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. [Errata, N Engl J Med 2001;345:1506, 1716.]
6. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
7. Sabatine MS, Cannon CP, Gibson M, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
8. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
9. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
10. Connolly SJ. The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W)-Non-inferiority trial versus oral anticoagulation. Presented at the Late-Breaking Clinical Trials III, American Heart Association Scientific Sessions 2005, Dallas, November 13-16, 2005.
11. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
12. Moyé LA. Statistical reasoning in medicine: the intuitive P-value primer. New York: Springer-Verlag, 2000.
13. Rothwell PM. Treating individuals. 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005;365:176-86.
14. Maseri A. Atillio Maseri, MD, FACC, discusses the role of biological clinical research in cardiovascular disease and the move from megatrials to personalized patient management. Circulation 2006;113:29-30.